Pfizer Inc. reports mixed late-stage results for two phase 3b Lyrica studies
Fibromyalgia study shows reduction in pain; diabetic peripheral neuropathy misses the mark
Register for free to listen to this article
Listen with Speechify
0:00
5:00
Pfizer Inc. announced top-line results from two phase IIIb, placebo-controlled studies with Lyrica (pregabalin) capsules CV in patients with fibromyalgia (FM) and painful diabetic peripheral neuropathy (DPN), respectively. The fibromyalgia study, A0081275 met its primary endpoint, showing a reduction in pain associated with fibromyalgia in patients who were treated concurrently with antidepressant therapy for comorbid depression. Separately, the painful DPN study, A0081269 did not meet its co-primary endpoints by sufficiently reducing DPN pain and DPN pain on walking compared to placebo.
